A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.
In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.
advertisement
Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
ReNAgade cuts staff seven months after raising $300 million
Next article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Trump demands the U.S. pay no more for drugs than other countries … again
